TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06529094

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider training
Description: Provider participants will complete TMS training, CAPP-FIT demonstration and simulation in use of the CAPP-FIT with a standardized patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAPP-FIT intervention with RA facilitation
Description: After consent and survey completion, RA to email/text CAPP-FIT link to Veteran the day before established clinic visit. RA to remain available to answer questions to help Veteran participant complete Veteran Survey and submit the responses through eScreening. The Provider Report will appear in CPRS with a Provider notification. RA to meet Veteran participant in the clinic after the clinic visit to complete the Veteran satisfaction survey.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAPP-FIT implementation during maintenance phase
Description: Providers will attend focus group after Arm 2 to determine sustainability of CAPP-FIT use in clinic workflow. Clinic provider will act on that determination for 10 months during maintenance phase.
Study: NCT04821141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene and Conjugated Estrogens
Description: BZA (20 mg) plus CE (0.45 mg) taken together once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Bazedoxifene and Conjugated Estrogens
Description: BZA (20 mg) plus CE (0.45 mg) taken together once daily
Study: NCT05580458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix is a recombinant, adjuvanted vaccine for prevention of herpes zoster. It is supplied as lyophilized recombinant VZV surface gE antigen for reconstitution with AS01B adjuvant suspension. Each Shingrix dose will be 0.5mL and administered by IM injection in the deltoid region of the upper arm.
Study: NCT05802550

Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Surface Disease Index
Description: Questionnaire on ocular surface disorders

Intervention type: OTHER
Group type: OTHER
Intervention: Interferometry
Description: Non-contact examination measuring NIBUT (non-invasive break-up time), meibography and tear meniscus measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Oxford score
Description: Investigation and quantification of superficial corneal punctate keratitis using the Oxford score

Intervention type: OTHER
Group type: OTHER
Intervention: Conjunctival collection
Description: Two conjunctival prints: one for metabolomic and one for lipidomic

Intervention type: OTHER
Group type: OTHER
Intervention: Aqueous humor collection
Description: Collection of 0.1 mL of aqueous humor immediately after making the accessory corneal incision at the beginning of the cataract surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Quantification of Tyndall and flare
Description: Quantification of Tyndall and flare (from 1 to 4 crosses) in anterior chamber
Study: NCT05353543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: In this study, SSRIs antidepressants will be used, and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture (strong reaction acupoints)
Description: This study will use the intradermal needle as an acupuncture intervention. Strong reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture (weak reaction acupoints)
Description: This study will use the intradermal needle as an acupuncture intervention. Weak reaction acupoints selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Sham acupuncture will use the same size, color, and material as the verum intradermal needle with a thin silicone pad in the middle instead of the needle body. The sham acupuncture will be needled on the points 1cm lateral to strong reaction acupoints. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. A total of 10 sessions will be performed for 6 weeks.
Study: NCT05838521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
Study: NCT06637436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Description: Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
Study: NCT06534502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide Oral Product
Description: Zonisamide oral suspension
Study: NCT05375292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREHABILITATION
Description: Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises.
Study: NCT05537038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT164a1
Description: Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT164b1
Description: Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06243848

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Incision Surgery for median nerve decompression
Description: Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perineural injection with 5 cc 5% Dextrose
Description: The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
Study: NCT06080737

Intervention type: OTHER
Intervention: quality of life questionnaire
Description: telephone interview to assess mortality and quality of life in the population included in a trial

Intervention type: OTHER
Intervention: quality of life questionnaire
Description: telephone interview to assess mortality and quality of life in the population included in a trial
Study: NCT05709691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor therapy
Description: Visual exercise to improve oculomotor behavior.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted yoga
Description: Muscular Stretching Therapy, postural control, respiratory physiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted yoga
Description: Muscular Stretching Therapy, postural control, respiratory physiotherapy.
Study: NCT05135169

Intervention type: DRUG
Intervention: Definity Suspension for Injection
Description: Administration of Definity
Study: NCT06186700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxiphylline tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets three times per day for the treatment period of neoadjuvant chemotherapy cycles of doxorubicin/ cyclophosphamide
Study: NCT05925387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CANAP Education
Description: The volunteer group included in the research consists of Yeditepe University Nursing Students. All nursing students over the age of 18, at all levels of the nursing program, will be included in the study based on voluntary participation, in accordance with the sample size. The purpose and design of the research will be explained to the 1st, 2nd, 3rd, and 4th-year nursing students. The announcement of the study will be made through Yeditepe University Nursing's social media accounts, and a consent link provided. Participants who sign the document in the consent link and upload it to the shared Google Drive received the pre-test link. Participants who complete all the procedures are provided with a participant certificate prepared by the researchers as an incentive.
Study: NCT05930587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Description: Cold water immersion (15 degree celsius, 20 minutes)
Study: NCT05284032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab 10 mg/kg
Description: Given by intravenous infusion
Study: NCT05957640

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Yttrium-90 carbon microspheres SIRT
Description: Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
Study: NCT05147246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps-Professional Development (PD)
Description: PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps-Professional Development (PD)
Description: PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
Study: NCT05200988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab + nivolumab
Description: Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy
Study: NCT05272514

Intervention type: OTHER
Intervention: Hypoxia
Description: Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
Study: NCT03332888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be studied in patients with HFrEF, and verify the patients safety.
Study: NCT05712824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-LAP™ SYSTEM
Description: Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
Study: NCT06098014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide Capsules
Description: To see safety and efficacy of Thalidomide in Transfusion depended thalassemia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: compare with Thalidomide
Study: NCT06057571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 (tinengotinib)
Description: TT-00420 (tinengotinib) tablet will be administered orally once daily per protocol defined schedule.
Study: NCT05564858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia
Description: FDA022-BB05, intravenously infusion, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
Description: FDA022-BB05, intravenously infusion, q3w
Study: NCT06392490

Intervention type: OTHER
Group type: OTHER
Intervention: Technology Based Asthma Program
Description: Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.

Intervention type: OTHER
Group type: OTHER
Intervention: Technology Based Asthma Program
Description: Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.
Study: NCT06260787

Intervention type: PROCEDURE
Intervention: In Vitro Fertilisation
Description: Assisted reproductive technology in the form of in vitro fertilisation
Study: NCT05388357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Procedure: PCI
Description: Percutaneous Coronary Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Procedure: PCI
Description: Percutaneous Coronary Intervention
Study: NCT05887635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Vapor Ablation
Description: RF Vapor ablation of the duodenum
Study: NCT05803941

Intervention type: DRUG
Group type: OTHER
Intervention: AAA617
Description: Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent clinical interventional Novartis sponsored clinical trials.
Study: NCT05613270

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FES PET/CT scan
Description: Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
Study: NCT06332443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation epidural anesthesia
Description: Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
Study: NCT05549388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling
Description: The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling
Description: The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack labeling
Description: The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
Study: NCT04880811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib is orally administered at 40mg Qd of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
Study: NCT06165367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EmbryoGlue Medium
Description: Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
Study: NCT05333341

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCM
Description: TCM care is remotely-delivered and medium-term (up to 12 months), with the objective of improving CP and OUD/misuse symptoms primarily through medication management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCM plus COPES
Description: The COPES program will augment the effectiveness of TCM alone. COPES is a 12-week, Interactive Voice Response (IVR)-facilitated program of CBT for CP and common sequelae (depressive symptoms, sleep difficulties, low physical activity). Ongoing COPES engagement will be tracked by the COPES system. The primary components of the intervention are: 1) a self-help handbook containing the rationale and instructions for using ten pain self-management skills and their corresponding weekly skill practice goals; 2) a pedometer-facilitated walking program; 3) daily, automated IVR calls to collect pain interference, sleep quality, pedometer-measured step count, and adherence to the pain coping skill practice ratings; and 4) weekly, two to four minute pre-recorded, personalized therapist messages based on participant IVR-reported data.
Study: NCT04747535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Description: AIrSense 10, Auto-CPAP, Minimum pressure 5 cm water, maximum pressure 10 cm water

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP since before
Description: A CPAP the patient uses since before because of previously diagnosed obstructive sleep apnea
Study: NCT05163743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Calorie Ketogenic Diet
Description: The very low-carbohydrate diet will be hypo caloric and aim to provide less than 50 g of carbohydrates per day. the participants will be counseled to choose vegetarian and healthy sources of fat and protein and to avoid trans fat. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
Study: NCT04704531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4% BID
Description: Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4% QID
Description: Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno QID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Ophthalmic 0.4% Six times per day
Description: Topical ophthalmic administration of one drop of Multidose Lagricel® Ofteno six times per day.